Precision Medicine Market Size to Hit USD 262.50 Billion by 2033

Precision Medicine Market Size, Share, Growth, Segmental Analysis, By Technology (Genomics — Next-Generation Sequencing, PCR, Microarray, Proteomics, Metabolomics, Pharmacogenomics, Bioinformatics and Big Data Analytics, Others), By Application (Oncology, Pharmacogenomics, CNS — Central Nervous System, Immunology, Cardiovascular Diseases, Rare Diseases, Others), By End User (Hospitals and Healthcare Providers, Pharmaceutical and Biotechnology Companies, Diagnostic Laboratories, Academic and Research Institutes, Contract Research Organizations), By Region (North America, Europe, Asia Pacific, Latin America, Middle East & Africa), and Market Forecast, 2026 – 2033

  • Published: Apr, 2026
  • Report ID: 443
  • Pages: 160+
  • Format: PDF / Excel.

This report contains the Latest Market Figures, Statistics, and Data.

Get a Sample
logo

Precision Medicine Market Size to Hit USD 262.50 Billion by 2033

(An Updated Version is Available)

1. Preface

  • 1.1 Report Description and Scope

  • 1.2 Research Objectives

  • 1.3 Key Assumptions and Limitations

  • 1.4 Target Audience

2. Executive Summary

  • 2.1 Market Overview and Snapshot

  • 2.2 Key Market Findings and Highlights

  • 2.3 Market Size Estimation and Forecast Summary

  • 2.4 Key Trends at a Glance

  • 2.5 Recommendations for Market Participants

3. Research Methodology

  • 3.1 Research Design and Approach

  • 3.2 Primary Research (Oncologists, Genomic Scientists, Pharma R&D Heads, KOL Interactions, Clinical Lab Directors)

  • 3.3 Secondary Research (Annual Reports, FDA DTPM/RMAT/510(k) Databases, EMA CAT, NIH/NHGRI, EFPIA Publications, ClinicalTrials.gov, IQVIA Oncology Intelligence)

  • 3.4 Top-Down and Bottom-Up Estimation Approach

  • 3.5 Data Triangulation and Validation

  • 3.6 Market Forecast Assumptions and Key Parameters

4. Market Overview

  • 4.1 Introduction to Precision Medicine and Its Role in Transforming Individualized Healthcare

  • 4.2 Historical Market Background and Evolution (One-Size-Fits-All → Genomics Era → AI-Omics Integrated Personalized Therapy)

  • 4.3 Market Scope and Definition

  • 4.4 Parent Market and Adjacent Market Analysis (Genomics, Companion Diagnostics, Cell & Gene Therapy, Pharmacogenomics, Digital Health)

  • 4.5 Regulatory Overview (FDA 21st Century Cures Act, RMAT Designation, EMA ATMP/CAT, ICH E15/E16, EU CTR 536/2014, ISO 15189, CLIA Waiver, GDPR/HIPAA Data Governance)

  • 4.6 Technology and Innovation Timeline (HGP Completion → NGS → Liquid Biopsy → CAR-T/Gene Editing → AI-Driven Omics)

  • 4.7 Traditional Medicine vs. Precision Medicine: Clinical Efficacy, Cost-Effectiveness, and Patient Outcome Comparison

5. Market Dynamics

  • 5.1 Market Drivers

    • 5.1.1 Rising Global Prevalence of Chronic Diseases (Cancer, CVD, Diabetes, Rare Diseases) Demanding Personalized Treatment Strategies

    • 5.1.2 Advancements in Next-Generation Sequencing (NGS), Multi-Omics, Liquid Biopsy, and Companion Diagnostics

    • 5.1.3 Accelerating FDA and EMA Regulatory Approvals for Targeted Therapies and Companion Diagnostics (Over 150 On-Label CDx Combinations)

    • 5.1.4 Growing Government Investments in Precision Health Programs (PMI, UK Genomics England, China 100,000 Genomes Project, Saudi Human Genome Program)

    • 5.1.5 Rapid Integration of AI, Machine Learning, and Big Data Analytics into Genomic Profiling and Drug Discovery Pipelines

    • 5.1.6 Significant Rise in R&D Spending by Pharma and Biotech Companies on Cell, Gene, and Targeted Therapy Programs

    • 5.1.7 Declining Cost of Whole-Genome Sequencing Democratizing Clinical Precision Diagnostics Beyond Major Academic Centers

  • 5.2 Market Restraints

    • 5.2.1 Ethical Concerns Around Genetic Data Privacy, Security Breaches, and Informed Consent Frameworks

    • 5.2.2 High Development Costs for Companion Diagnostics, Gene Therapies, and CAR-T Products Limiting Broad Access

    • 5.2.3 Limited Health Insurance Coverage and Reimbursement for Genomic Tests and Precision Therapeutics in Emerging Markets

    • 5.2.4 Regulatory Ambiguity Around Multi-Omic AI-Driven Diagnostic Tools and Autologous Cell Therapy Products

    • 5.2.5 Data Interoperability Gaps Across EHR Systems, Biobanks, and Genomic Databases Hampering Population-Level Insights

  • 5.3 Market Opportunities

    • 5.3.1 Expansion of Cell and Gene Therapy into Rare Diseases, Hematology, and Solid Tumor Oncology (CAR-T, CRISPR-Cas9, AAV Gene Therapy)

    • 5.3.2 AI and Generative AI-Driven Drug Target Discovery, Patient Stratification, and Biomarker Identification Platforms (Tempus, Foundation Medicine, Nucleai)

    • 5.3.3 Liquid Biopsy as Non-Invasive Real-Time Companion Diagnostic for Recurrence Monitoring, Early Detection, and MRD Assessment

    • 5.3.4 Pharmacogenomics in Primary Care — Integrating PGx Panels into EHRs for Safer Prescribing and Adverse Drug Reaction Prevention

    • 5.3.5 Precision Medicine Expansion Beyond Oncology into CNS, Cardiovascular, Endocrinology, and Autoimmune Indications

    • 5.3.6 Emerging Markets (China, India, Brazil, Saudi Arabia) Launching National Genomics and Precision Oncology Programs

    • 5.3.7 Growth of Population-Scale Biobanks and Real-World Evidence Repositories for Multi-Ethnic Drug Discovery

  • 5.4 Market Challenges

    • 5.4.1 Cross-Border Genetic Data Transfer Restrictions (EU GDPR, China PIPL, India DPDPA) Complicating Multi-National Precision Research Programs

    • 5.4.2 Physician Education Gaps in Genomic Medicine Interpretation and Companion Diagnostic Result Utilization

    • 5.4.3 Complex Manufacturing and Quality Control Requirements for Personalized Cell and Gene Therapy Products at Scale

    • 5.4.4 Ensuring Health Equity and Reducing Racial/Ethnic Bias in Genomic Reference Databases for Diverse Population Coverage

6. Market Trends and Key Insights

  • 6.1 Rapid Growth of Cell and Gene Therapy Approvals — CAR-T (Kymriah, Yescarta), Gene Editing (Casgevy, Lyfgenia), and AAV Therapies

  • 6.2 AI-Powered Precision Medicine Platforms (Tempus AI, Nucleai, BostonGene) Enabling Tumor Microenvironment and Spatial Biology Analysis

  • 6.3 Liquid Biopsy Emerging as the Cornerstone of Non-Invasive Companion Diagnostics for Early Cancer Detection and Treatment Monitoring

  • 6.4 Pharmacogenomics Integration into Clinical Workflows — PGx-Based Drug Selection, Dosing Optimization, and Opioid Management

  • 6.5 Expansion of Multi-Cancer Early Detection (MCED) Platforms (GRAIL Galleri, Guardant SHIELD) into National Screening Programs

  • 6.6 Growing Use of Digital Biomarkers and Wearable Data for Continuous Longitudinal Patient Phenotyping

  • 6.7 Precision Medicine Moving Beyond Oncology — CNS, Cardiovascular, Rare Disease, and Metabolic Condition Applications

  • 6.8 Global Convergence of National Population Genomics Programs Enabling Cross-Continental Drug Discovery Datasets

7. Impact Assessment

  • 7.1 Impact of COVID-19 on the Precision Medicine Market

    • 7.1.1 Pre-COVID Market Scenario

    • 7.1.2 Pandemic Impact: Accelerated Genomic Sequencing, mRNA Platform Development, and AI-Based Variant Surveillance

    • 7.1.3 Post-COVID Strategic Realignment: Expanded AI-Omics Investments, Global Biobank Growth, and Gene Therapy Pipeline Expansion

  • 7.2 Macroeconomic Indicators and Their Influence on Market Growth

  • 7.3 Impact of FDA RMAT, Inflation Reduction Act (IRA) Drug Price Negotiations, and EU EHDS (European Health Data Space) on Market Access

  • 7.4 Geopolitical Factors — China PIPL, U.S. BIOSECURE Act (BGI, MGI Technologies), and Cross-Border Genomic Data Sovereignty Policies

8. Strategic Framework Analysis

  • 8.1 Value Chain Analysis

    • 8.1.1 Genomic and Biological Sample Collection (Biobanks, Clinical Labs, Direct-to-Consumer Kits)

    • 8.1.2 Genomic Sequencing and Multi-Omics Analysis (NGS, Proteomics, Metabolomics, Epigenomics)

    • 8.1.3 Bioinformatics and AI-Driven Data Interpretation Platforms

    • 8.1.4 Companion Diagnostic Developers and Regulatory Partners

    • 8.1.5 Precision Therapeutics and Targeted Drug Developers

    • 8.1.6 Clinical Delivery Networks (Hospitals, AMCs, Specialty Oncology Centers)

    • 8.1.7 Payers, Regulators, and Health Technology Assessment (HTA) Bodies

  • 8.2 Supply Chain Analysis and Risk Assessment

  • 8.3 Porter's Five Forces Analysis

    • 8.3.1 Threat of New Entrants (AI-Native Genomics Startups, CRISPR Platform Companies)

    • 8.3.2 Bargaining Power of Buyers (Hospital Networks, National Payer Systems)

    • 8.3.3 Bargaining Power of Suppliers (Sequencing Hardware Vendors, Biological Reagent Manufacturers)

    • 8.3.4 Threat of Substitutes (Traditional Drug Therapies, Population-Based Screening)

    • 8.3.5 Competitive Rivalry Among Existing Players

  • 8.4 SWOT Analysis of the Overall Market

  • 8.5 Pricing Analysis and Trends by Product, Technology, and Region

  • 8.6 Technology Landscape and Innovation Matrix

    • 8.6.1 Next-Generation Sequencing (NGS) and Whole-Genome/Exome Sequencing Platforms

    • 8.6.2 Liquid Biopsy — ctDNA, cfRNA, Circulating Tumor Cells (CTCs), and MRD Detection

    • 8.6.3 AI and Generative AI in Genomic Data Interpretation, Target Discovery, and Drug Development

    • 8.6.4 CRISPR-Cas9 and Base/Prime Editing for Therapeutic Genome Correction

    • 8.6.5 CAR-T and TCR-T Cell Therapy Manufacturing and Engineering Platforms

    • 8.6.6 Companion Diagnostics — Co-Development, Regulatory Submission, and Commercialization

    • 8.6.7 Digital Biomarker and Wearable Device Integration for Continuous Phenotyping

  • 8.7 IP and Patent Landscape

  • 8.8 Pipeline Analysis — Clinical Trials, Investigational Therapies, and Precision CDx in Development (FDA, EMA, PMDA Data)

  • 8.9 Regulatory and Standards Landscape by Region (FDA RMAT/510(k), EMA ATMP/CAT, PMDA, CDSCO, NMPA, ISO 15189, CLIA, ICH E15/E16)

  • 8.10 Drivers Impact Analysis on CAGR

9. Global Precision Medicine Market — By Product

  • 9.1 Overview and Market Size, 2026–2033

  • 9.2 Devices

    • 9.2.1 NGS Sequencing Systems and Instruments

    • 9.2.2 Diagnostic Imaging Systems (PET-CT, MRI, Digital Pathology)

    • 9.2.3 Wearable and Remote Monitoring Devices for Patient Phenotyping

    • 9.2.4 Companion Diagnostic Devices

    • 9.2.5 Market Size, Share, and Forecast (58.25% Dominant Share: Broad Utility Across Diagnostics, Monitoring, and Clinical Workflows)

  • 9.3 Drugs

    • 9.3.1 Monoclonal Antibodies

    • 9.3.2 Targeted Small Molecule Therapies

    • 9.3.3 Gene Therapy Products (AAV, Lentiviral, Ex-Vivo)

    • 9.3.4 Cell Therapy Products (CAR-T, TCR-T, NK Cell)

    • 9.3.5 Antibody-Drug Conjugates (ADCs)

    • 9.3.6 Market Size, Share, and Forecast

  • 9.4 Software and AI Platforms

    • 9.4.1 Genomic Data Analytics and Interpretation Platforms

    • 9.4.2 AI-Driven Clinical Decision Support (Tempus, Nucleai, Foundation Medicine AI Suite)

    • 9.4.3 Electronic Health Record (EHR) Integrated Precision Insights Platforms

    • 9.4.4 Market Size, Share, and Forecast

    • 9.4.5 Fastest Growing Product (Significant CAGR): AI-EHR Integration, GenAI Drug Target Discovery, and Digital Health Convergence

10. Global Precision Medicine Market — By Type

  • 10.1 Overview and Market Size, 2026–2033

  • 10.2 Diagnostics

    • 10.2.1 Genetic Tests

      • 10.2.1.1 Predictive and Presymptomatic Tests (BRCA1/2, Lynch Syndrome, Pharmacogenomics)

      • 10.2.1.2 Carrier Testing

      • 10.2.1.3 Prenatal and Newborn Screening (Cell-Free DNA, NIPS)

      • 10.2.1.4 Other Genetic Tests (Ancestry, Pathogen Genomics, DTC Kits — 23andMe, AncestryDNA)

    • 10.2.2 Biomarker Tests

      • 10.2.2.1 Screening Tests (Multi-Cancer Early Detection — GRAIL Galleri, Guardant SHIELD)

      • 10.2.2.2 Recurrence Monitoring (Liquid Biopsy, ctDNA MRD Assessment)

      • 10.2.2.3 Therapy Selection (Companion Diagnostics — FoundationOne CDx, Oncomine Dx, TruSight Oncology)

      • 10.2.2.4 Esoteric Tests (Rare Genomic Disorder Panels, Orphan Disease Biomarker Assays)

      • 10.2.2.5 Others (Proteomics, Metabolomics, Microbiome Profiling Tests)

    • 10.2.3 Market Size, Share, and Forecast (47.49% Dominant Share: Essential Role in Personalized Treatment Decision-Making)

  • 10.3 Therapeutics

    • 10.3.1 Monoclonal Antibodies (PD-1/PD-L1, HER2, EGFR, VEGF Targeted MAbs)

    • 10.3.2 Gene Therapy (AAV, Lentiviral, CRISPR-Enabled Gene Correction — Casgevy, Luxturna, Zolgensma)

    • 10.3.3 Cell Therapy (CAR-T — Kymriah, Yescarta, Breyanzi; NK Cell, TCR-T Therapies)

    • 10.3.4 Other Targeted Biologics and ADCs

    • 10.3.5 Market Size, Share, and Forecast (CAGR of 15.8% per GVR: Expanding CDx-Drug Launch Pairs and CAR-T Pipelines)

  • 10.4 Research Tools and Platforms

    • 10.4.1 Multi-Omics Research Tools (Genomics, Transcriptomics, Proteomics, Metabolomics)

    • 10.4.2 Biobank and Bio-Repository Platforms

    • 10.4.3 Clinical-Translational Research Platforms

    • 10.4.4 Market Size, Share, and Forecast

11. Global Precision Medicine Market — By Application / Indication

  • 11.1 Overview and Market Size, 2026–2033

  • 11.2 Oncology

    • 11.2.1 Breast Cancer (HER2+, BRCA-Mutated)

    • 11.2.2 Lung Cancer (EGFR, ALK, ROS1, PD-L1 Targeted Therapies)

    • 11.2.3 Colorectal Cancer (MSI-H, KRAS-Wild Type, BRAF-Mutated)

    • 11.2.4 Hematologic Malignancies (Leukemia, Lymphoma — CAR-T Dominance)

    • 11.2.5 Prostate, Ovarian, and Pancreatic Cancer (BRCA, PSMA-Targeted Approaches)

    • 11.2.6 Market Size, Share, and Forecast (31.93% Dominant Share: Largest Clinical Trial Activity and CDx Approvals)

  • 11.3 Neurology and Psychiatry

    • 11.3.1 Alzheimer's and Neurodegeneration (APOE4 Genotyping, Amyloid PET Imaging, Gene Therapy Trials)

    • 11.3.2 Epilepsy (Genetic Channelopathy Panels, Precision Anti-Seizure Drug Selection)

    • 11.3.3 Psychiatric Genomics (Pharmacogenomics in Depression, Schizophrenia, ADHD)

    • 11.3.4 Market Size, Share, and Forecast

  • 11.4 Immunology

    • 11.4.1 Rheumatoid Arthritis (Anti-TNF, IL-6 Inhibition, Precision Biologic Selection)

    • 11.4.2 Inflammatory Bowel Disease (Anti-Integrin, JAK Inhibitor Precision Dosing)

    • 11.4.3 Autoimmune Rare Diseases (Complement, Type I IFN Pathway Precision Therapies)

    • 11.4.4 Market Size, Share, and Forecast

  • 11.5 Cardiology

    • 11.5.1 Inherited Cardiac Conditions (HCM, DCM, Channelopathies — CRISPR Trials)

    • 11.5.2 Precision Anti-Thrombotic and Anti-Lipid Therapy (Pharmacogenomics-Guided Prescribing)

    • 11.5.3 Market Size, Share, and Forecast

  • 11.6 Endocrinology

    • 11.6.1 Diabetes (Precision Insulin Dosing, Monogenic Diabetes Genetic Testing)

    • 11.6.2 Thyroid and Rare Endocrine Tumors

    • 11.6.3 Market Size, Share, and Forecast

  • 11.7 Others (Respiratory Diseases, Infectious Disease Genomics, Rare Genetic Disorders, Ophthalmology, Dermatology)

12. Global Precision Medicine Market — By End User

  • 12.1 Overview and Market Size, 2026–2033

  • 12.2 Pharmaceutical and Biopharmaceutical Companies

    • 12.2.1 Market Size, Share, and Forecast (54.93% Dominant Share)

    • 12.2.2 Key Drivers: Internal R&D, Companion Diagnostic Co-Development, Clinical Trial Patient Stratification

  • 12.3 Diagnostic Laboratories

    • 12.3.1 Reference and Esoteric Testing Laboratories

    • 12.3.2 Hospital-Based Molecular Pathology Labs

    • 12.3.3 Market Size, Share, and Forecast

    • 12.3.4 Key Role: CDx Sample Processing, Biomarker Reporting, and NGS-Based Oncology Panel Testing

  • 12.4 Contract Research Organizations (CROs)

    • 12.4.1 Market Size, Share, and Forecast

    • 12.4.2 Biomarker Discovery, Patient Stratification, CDx Co-Development, and Precision Clinical Trial Design

  • 12.5 Hospitals and Academic Medical Centers

    • 12.5.1 Market Size, Share, and Forecast (60.0% of End-Use Revenue per GVR: High Infrastructure, Research Access)

    • 12.5.2 Precision Oncology Clinics, Multidisciplinary Tumor Boards, and Genomics Counseling Services

  • 12.6 Home Care Settings

    • 12.6.1 Market Size, Share, and Forecast (Fastest Growing End User per GVR: Telemedicine, Wearables, At-Home Genetic Test Kits)

    • 12.6.2 Remote Monitoring, DTC Genetic Testing (23andMe, AncestryDNA), and Self-Managed Chronic Disease Platforms

  • 12.7 Others (Payers, Health Technology Assessors, Research Institutes, Population Genomics Programs)

13. Global Precision Medicine Market — By Region

  • 13.1 Market Overview by Geography

  • 13.2 North America

    • 13.2.1 Market Size and Forecast (53.62% Dominant Share — USD 51.25 Billion in 2025)

    • 13.2.2 United States (~39.0% of Global Revenue; FDA DTPM, PMI, AHA Precision CVD Program)

    • 13.2.3 Canada

    • 13.2.4 Mexico

    • 13.2.5 Key Drivers, Trends, and Market Dynamics

  • 13.3 Europe

    • 13.3.1 Market Size and Forecast (~24.35% Share — USD 24.31 Billion in 2025)

    • 13.3.2 Germany (~USD 6.88 Billion in 2026; EuroBioForum, German Center for Infection Research)

    • 13.3.3 United Kingdom (~USD 4.7 Billion in 2026; Genomics England, NHS Personalized Medicine Program)

    • 13.3.4 France

    • 13.3.5 Italy

    • 13.3.6 Spain

    • 13.3.7 Scandinavia (Denmark, Sweden, Norway)

    • 13.3.8 Rest of Europe

    • 13.3.9 Key Drivers, Trends, and Market Dynamics (EU EHDS, EFPIA Precision Medicine Charter)

  • 13.4 Asia Pacific

    • 13.4.1 Market Size and Forecast (Fastest Growing — ~14.29% Share, USD 14.27 Billion in 2025)

    • 13.4.2 China (~USD 6.06 Billion in 2026; 100,000 Genomes Project, NMPA Precision Drug Approvals)

    • 13.4.3 India (~USD 2.25 Billion in 2026; Apollo AI Precision Oncology Centre, CDSCO CDx Approvals)

    • 13.4.4 Japan (~USD 3.2 Billion in 2026; PMDA Gene Therapy Fast Track, Sakura Genome Program)

    • 13.4.5 South Korea

    • 13.4.6 Australia and New Zealand

    • 13.4.7 Southeast Asia (Thailand, Singapore, Vietnam)

    • 13.4.8 Rest of Asia Pacific

    • 13.4.9 Key Drivers, Trends, and Market Dynamics

  • 13.5 Latin America

    • 13.5.1 Market Size and Forecast (~6.04% Share, USD 6.03 Billion in 2025)

    • 13.5.2 Brazil (BeiGene Latin America Expansion, Genomic Epidemiology Research Programs)

    • 13.5.3 Mexico

    • 13.5.4 Argentina

    • 13.5.5 Rest of Latin America

    • 13.5.6 Key Drivers, Trends, and Market Dynamics

  • 13.6 Middle East & Africa

    • 13.6.1 Market Size and Forecast (~3.98% Share, USD 3.98 Billion in 2025)

    • 13.6.2 Saudi Arabia (Saudi Human Genome Program, NIDCenter Healthcare Investment)

    • 13.6.3 United Arab Emirates

    • 13.6.4 South Africa (Artisan Biomed — CPGR Acquisition by Mediclinic)

    • 13.6.5 Kuwait

    • 13.6.6 Rest of Middle East & Africa

    • 13.6.7 Key Drivers, Trends, and Market Dynamics

14. Competitive Landscape

  • 14.1 Market Structure and Competitiveness Overview (Highly Fragmented: Diagnostics Giants + Pharma Majors + AI Biotech Startups)

  • 14.2 Market Share Analysis of Key Players

  • 14.3 Competitive Positioning Matrix

  • 14.4 Key Strategies Adopted by Market Leaders

    • 14.4.1 Companion Diagnostic Co-Development with Pharma Partners (Illumina-Janssen, QIAGEN-Inovio, Thermo Fisher-AstraZeneca)

    • 14.4.2 AI-Powered Clinical Genomics Platforms — Foundation Medicine (FoundationOne CDx), Tempus AI, Nucleai-Mayo Clinic

    • 14.4.3 Strategic Acquisitions to Build End-to-End Precision Medicine Portfolios (Lilly-Akouos, Agilent-Avida Biomed, Roche-Blueprint Medicines)

    • 14.4.4 Government and NGO Program Participation (UK Genomics England, Saudi HGP, NIH All of Us, China BGI Genome Programs)

    • 14.4.5 Expansion of Cell and Gene Therapy Pipelines with FDA/EMA Accelerated Approval Pathway Strategies

  • 14.5 Recent Developments and Industry News (2024–2026)

  • 14.6 Technology and Pipeline Analysis

15. Company Profiles
(The final report includes a complete list of companies)

  • 15.1 F. Hoffmann-La Roche Ltd. (Foundation Medicine)

    • 15.1.1 Company Overview

    • 15.1.2 Financial Performance

    • 15.1.3 Product Portfolio

    • 15.1.4 Strategic Initiatives

    • 15.1.5 SWOT Analysis

  • 15.2 Illumina, Inc.

  • 15.3 Thermo Fisher Scientific Inc.

  • 15.4 QIAGEN N.V.

  • 15.5 Novartis AG

  • 15.6 Pfizer Inc.

  • 15.7 AstraZeneca PLC

  • 15.8 Bristol-Myers Squibb Company

  • 15.9 Agilent Technologies, Inc.

  • 15.10 Myriad Genetics, Inc.

  • 15.11 Guardant Health, Inc.

  • 15.12 Tempus AI, Inc.

  • 15.13 Natera, Inc.

  • 15.14 Adaptive Biotechnologies Corporation

  • 15.15 Quest Diagnostics Incorporated

16. Appendix

  • 16.1 Abbreviations and Acronyms

  • 16.2 List of Tables

  • 16.3 List of Figures

  • 16.4 About the Publisher

  • 16.5 Research Process and Data Sources

17. Disclaimer

Enhance your decision-making capabilities with a 5 Reports-in-1
Bundle deal for - more than 40% off!

Our professional analysts will provide you with immediate assistance.